SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Baker who wrote (1870)9/29/1997 9:07:00 AM
From: margie   of 6136
 
Appreciate your input. Glad that you agree that giving such a small preliiminary study undue study is a journalistic shame.
The part about open label were not my comments. I was repeating verbatim from this reporter's article: "The study was "open-label," meaning that it wasn't double-blinded or placebo-controlled, and as such is analogous to database analysis rather than a rigorous clinical trial. " end quote

If it is true that Viracept does not have as favorable a cross-resistance profile as thought, I and many others would be disappointed but so be it. More clinical studies are necessary to settle this question. I agree with you that resistance studies should provide a measured lab result. Do you think the study they described provides this?There are clinical studies that will be presented at this ICAAC, on the subject of Viracept and cross-resistance, that are supposed to report a very favorable cross-resistance profile for Viracept. Hope someone from the press covers those studies.

As far as Merck being a sponsor of Medscape, all I said was that
it's very unlikely they will cover presentations involving Viracept, since there will be many simultaneous presentations and sessions, and it is only natural they will cover studies involving Crixivan. I looked at the list of events to be covered by Medscape reporters, listed in the Medscape site, and did not think that there was any coverage of studies including Viracept. I could be wrong, it would be great if they did cover some, maybe they will.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News